-
2
-
-
0027483467
-
Screening, diagnosis, and staging of lung cancer
-
Shepherd FA. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993; 5: 310-322.
-
(1993)
Curr Opin Oncol
, vol.5
, pp. 310-322
-
-
Shepherd, F.A.1
-
3
-
-
0028139448
-
Chemotherapy for advanced non-small-cell lung cancer
-
Walling J. Chemotherapy for advanced non-small-cell lung cancer. Respir Med 1994; 88: 649-657.
-
(1994)
Respir Med
, vol.88
, pp. 649-657
-
-
Walling, J.1
-
4
-
-
0028843552
-
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-small Cell Lung Cancer Collaborative Group
-
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
-
(1995)
BMJ
, vol.311
, pp. 899-909
-
-
-
5
-
-
0027367248
-
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
-
Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1866-1872
-
-
Grilli, R.1
Oxman, A.D.2
Julian, J.A.3
-
6
-
-
0028031433
-
Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
-
Marino P, Pampallona S, Preatoni A et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
-
(1994)
Chest
, vol.106
, pp. 861-865
-
-
Marino, P.1
Pampallona, S.2
Preatoni, A.3
-
7
-
-
0027210487
-
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
-
Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
-
(1993)
Lancet
, vol.342
, pp. 19-21
-
-
Souquet, P.J.1
Chauvin, F.2
Boissel, J.P.3
-
8
-
-
0036729263
-
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial
-
Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3578-3585
-
-
Kosmidis, P.1
Mylonakis, N.2
Nicolaides, C.3
-
9
-
-
39049111157
-
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
-
Kosmidis PA, Kalofonos HP, Christodoulou C et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008; 19: 115-122.
-
(2008)
Ann Oncol
, vol.19
, pp. 115-122
-
-
Kosmidis, P.A.1
Kalofonos, H.P.2
Christodoulou, C.3
-
10
-
-
0036843105
-
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
-
Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4285-4291
-
-
Scagliotti, G.V.1
De Marinis, F.2
Rinaldi, M.3
-
11
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
12
-
-
37549030869
-
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials
-
Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59: 1-11.
-
(2008)
Lung Cancer
, vol.59
, pp. 1-11
-
-
Rajeswaran, A.1
Trojan, A.2
Burnand, B.3
Giannelli, M.4
-
13
-
-
19444365516
-
Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
-
D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2926-2936
-
-
D'Addario, G.1
Pintilie, M.2
Leighl, N.B.3
-
14
-
-
0029558573
-
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial
-
Gatzemeier U, Heckmayer M, Neuhauss R et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol 1995; 22: 24-28.
-
(1995)
Semin Oncol
, vol.22
, pp. 24-28
-
-
Gatzemeier, U.1
Heckmayer, M.2
Neuhauss, R.3
-
15
-
-
0027412646
-
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
-
Murphy WK, Fossella FV, Winn RJ et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 384-388
-
-
Murphy, W.K.1
Fossella, F.V.2
Winn, R.J.3
-
16
-
-
0026333741
-
Taxol: twenty years later, the story unfolds
-
Rowinsky EK, Donehower RC. Taxol: twenty years later, the story unfolds. J Natl Cancer Inst 1991; 83: 1778-1781.
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 1778-1781
-
-
Rowinsky, E.K.1
Donehower, R.C.2
-
17
-
-
0033950286
-
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial
-
Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
-
(2000)
J Clin Oncol
, vol.18
, pp. 623-631
-
-
Bonomi, P.1
Kim, K.2
Fairclough, D.3
-
18
-
-
0025146178
-
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
-
Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1556-1562
-
-
Klastersky, J.1
Sculier, J.P.2
Lacroix, H.3
-
19
-
-
0027360291
-
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting
-
Rowinsky EK, Chaudhry V, Forastiere AA et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010-2020.
-
(1993)
J Clin Oncol
, vol.11
, pp. 2010-2020
-
-
Rowinsky, E.K.1
Chaudhry, V.2
Forastiere, A.A.3
-
20
-
-
0027993707
-
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study
-
Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-1540.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1535-1540
-
-
Abratt, R.P.1
Bezwoda, W.R.2
Falkson, G.3
-
21
-
-
0028033227
-
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study
-
Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-1826.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1821-1826
-
-
Anderson, H.1
Lund, B.2
Bach, F.3
-
22
-
-
0029914387
-
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study
-
Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-248.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 243-248
-
-
Gatzemeier, U.1
Shepherd, F.A.2
Le Chevalier, T.3
-
23
-
-
0033737428
-
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer
-
Shepherd FA, Abratt R, Crino L et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000; 30: 117-125.
-
(2000)
Lung Cancer
, vol.30
, pp. 117-125
-
-
Shepherd, F.A.1
Abratt, R.2
Crino, L.3
-
24
-
-
0031032211
-
Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer
-
Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-749.
-
(1997)
J Clin Oncol
, vol.15
, pp. 744-749
-
-
Abratt, R.P.1
Bezwoda, W.R.2
Goedhals, L.3
Hacking, D.J.4
-
25
-
-
17344384670
-
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study
-
Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303.
-
(1997)
J Clin Oncol
, vol.15
, pp. 297-303
-
-
Crino, L.1
Scagliotti, G.2
Marangolo, M.3
-
26
-
-
0000292636
-
Activity and tolerability of gemcitabine plus weekly cisplatin in advanced non-small cell lung cancer
-
(Abstr)
-
Green M, Eisenberg P, Kosty M et al. Activity and tolerability of gemcitabine plus weekly cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 468 (Abstr).
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
, pp. 468
-
-
Green, M.1
Eisenberg, P.2
Kosty, M.3
-
27
-
-
0032983664
-
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-smallcell lung cancer
-
Kroep JR, Giaccone G, Voorn DA et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-smallcell lung cancer. J Clin Oncol 1999; 17: 2190-2197.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2190-2197
-
-
Kroep, J.R.1
Giaccone, G.2
Voorn, D.A.3
-
28
-
-
0036806170
-
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer
-
Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 73-77.
-
(2002)
Lung Cancer
, vol.38
, pp. 73-77
-
-
Bhatia, S.1
Hanna, N.2
Ansari, R.3
-
29
-
-
0000327539
-
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors
-
(Abstr)
-
Einhorn L, Raghavan D, Kindler H et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 1998; 17: 796 (Abstr).
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
, pp. 796
-
-
Einhorn, L.1
Raghavan, D.2
Kindler, H.3
-
30
-
-
0001039680
-
Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer
-
(Abstr 1869)
-
Giaccone G, Smit EF, Laan D et al. Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: (Abstr 1869).
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Giaccone, G.1
Smit, E.F.2
Laan, D.3
-
31
-
-
7344264012
-
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
-
Rothenberg ML, Sharma A, Weiss GR et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 9: 733-738.
-
(1998)
Ann Oncol
, vol.9
, pp. 733-738
-
-
Rothenberg, M.L.1
Sharma, A.2
Weiss, G.R.3
-
32
-
-
0003202030
-
Phase II study of carboplatin (C)-gemcitabine (G) in advanced non-small cell lung cancer (NSCLC)
-
(Abstr 2107)
-
Domine M, Casado V, Esteves L. Phase II study of carboplatin (C)-gemcitabine (G) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: (Abstr 2107).
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Domine, M.1
Casado, V.2
Esteves, L.3
-
33
-
-
0347600552
-
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer
-
Mott FE, Cable CT, Sharma N. Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer 2003; 5: 174-176.
-
(2003)
Clin Lung Cancer
, vol.5
, pp. 174-176
-
-
Mott, F.E.1
Cable, C.T.2
Sharma, N.3
-
34
-
-
33244494814
-
Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules
-
Obasaju CK, Ye Z, Bloss LP et al. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules. Clin Lung Cancer 2005; 7: 202-207.
-
(2005)
Clin Lung Cancer
, vol.7
, pp. 202-207
-
-
Obasaju, C.K.1
Ye, Z.2
Bloss, L.P.3
-
35
-
-
0024440650
-
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
-
Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1748-1756
-
-
Calvert, A.H.1
Newell, D.R.2
Gumbrell, L.A.3
-
36
-
-
0344405536
-
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines.
-
American Society of Clinical Oncology.
-
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957-1960.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1957-1960
-
-
Sudha, R.1
-
38
-
-
33645762226
-
A sharper Bonferroni procedure for multiple tests of significance
-
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-802.
-
(1988)
Biometrika
, vol.75
, pp. 800-802
-
-
Hochberg, Y.1
-
39
-
-
0018687930
-
A multiple testing procedure for clinical trials
-
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
-
(1979)
Biometrics
, vol.35
, pp. 549-556
-
-
O'Brien, P.C.1
Fleming, T.R.2
-
40
-
-
33845382806
-
Nonparametric estimation of incomplete observations
-
Kaplan E, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
41
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
-
42
-
-
77949589851
-
-
Cancer Therapy Evaluation Program. NCI Common Toxicity Criteria Version 2.0
-
Cancer Therapy Evaluation Program. NCI Common Toxicity Criteria Version 2.0. 1999.
-
(1999)
-
-
-
43
-
-
0029042825
-
Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
-
Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
-
(1995)
Lung Cancer
, vol.12
, pp. 199-220
-
-
Cella, D.F.1
Bonomi, A.E.2
Lloyd, S.R.3
-
44
-
-
66249139985
-
Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)
-
2007 ASCO Annual Meeting Proceedings Part I(Abstr 7665)
-
Ansari R, Goning R, Socinski MA et al. Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Suppl 18): 2007 ASCO Annual Meeting Proceedings Part I(Abstr 7665).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL 18
-
-
Ansari, R.1
Goning, R.2
Socinski, M.A.3
-
45
-
-
77949597762
-
Subgroup analysis of African American patients from a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to P plus Cb in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC)
-
2007 ASCO Annual Meeting Proceedings Part I (Abstr 7665)
-
Treat J, Goning R, Edelman M et al. Subgroup analysis of African American patients from a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to P plus Cb in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Suppl 18): 2007 ASCO Annual Meeting Proceedings Part I (Abstr 7665).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL 18
-
-
Treat, J.1
Goning, R.2
Edelman, M.3
-
46
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
-
Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
-
47
-
-
0035849269
-
Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
-
Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.
-
(2001)
Lancet
, vol.357
, pp. 1478-1484
-
-
Georgoulias, V.1
Papadakis, E.2
Alexopoulos, A.3
-
48
-
-
33750224010
-
CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatinbased chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)
-
2006 ASCO Annual Meeting Proceedings Part I(Abstr 7011)
-
Ardizzoni A, Tiseo M, Boni L et al. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatinbased chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18S): 2006 ASCO Annual Meeting Proceedings Part I(Abstr 7011).
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
-
-
Ardizzoni, A.1
Tiseo, M.2
Boni, L.3
-
49
-
-
5444235920
-
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer
-
Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3852-3859
-
-
Hotta, K.1
Matsuo, K.2
Ueoka, H.3
-
50
-
-
10844259259
-
Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients
-
2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)(Abstr 7068)
-
Zojwalla N, Raftopoulos H, Gralla R. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. J Clin Oncol 2004; 22(14S): 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)(Abstr 7068).
-
(2004)
J Clin Oncol
, vol.22
, Issue.14 S
-
-
Zojwalla, N.1
Raftopoulos, H.2
Gralla, R.3
-
51
-
-
77949588953
-
Gemcitabine (G) plus carboplatin (C) at AUC 5 demonstrates reduced grade 4 thrombocytopenia rate compared to AUC 5.5 in first line therapy of patients with advanced stage NSCLC
-
2006 ASCO Annual Meeting Proceedings Part I(Abstr 7130)
-
Treat J, Belani C, Schiller J et al. Gemcitabine (G) plus carboplatin (C) at AUC 5 demonstrates reduced grade 4 thrombocytopenia rate compared to AUC 5.5 in first line therapy of patients with advanced stage NSCLC. J Clin Oncol 2006; 24 (18 Suppl): 2006 ASCO Annual Meeting Proceedings Part I(Abstr 7130).
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 SUPPL
-
-
Treat, J.1
Belani, C.2
Schiller, J.3
-
52
-
-
34547780057
-
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
-
Azuma K, Komohara Y, Sasada T et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007; 98: 1336-1343.
-
(2007)
Cancer Sci
, vol.98
, pp. 1336-1343
-
-
Azuma, K.1
Komohara, Y.2
Sasada, T.3
-
53
-
-
34447573875
-
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer
-
Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2747-2754
-
-
Cobo, M.1
Isla, D.2
Massuti, B.3
-
54
-
-
34447567414
-
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer
-
Simon G, Sharma A, Li X et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 2741-2746.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2741-2746
-
-
Simon, G.1
Sharma, A.2
Li, X.3
-
55
-
-
0029950085
-
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials
-
Tejeda HA, Green SB, Trimble EL et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996; 88: 812-816.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 812-816
-
-
Tejeda, H.A.1
Green, S.B.2
Trimble, E.L.3
-
56
-
-
25444511051
-
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
-
Belani CP, Lee JS, Socinski MA et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16: 1069-1075.
-
(2005)
Ann Oncol
, vol.16
, pp. 1069-1075
-
-
Belani, C.P.1
Lee, J.S.2
Socinski, M.A.3
-
57
-
-
0035397994
-
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial
-
Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3210-3218
-
-
Kelly, K.1
Crowley, J.2
Bunn P.A., Jr.3
-
58
-
-
16644396077
-
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)
-
Lilenbaum RC, Herndon JE II, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.
-
(2005)
J Clin Oncol
, vol.23
, pp. 190-196
-
-
Lilenbaum, R.C.1
Herndon J.E. II2
List, M.A.3
-
59
-
-
0016160043
-
Proceedings: frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma
-
Newman SJ, Hansen HH. Proceedings: frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974; 33: 492-496.
-
(1974)
Cancer
, vol.33
, pp. 492-496
-
-
Newman, S.J.1
Hansen, H.H.2
-
60
-
-
0024271627
-
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis
-
Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474-1480.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1474-1480
-
-
Sorensen, J.B.1
Hansen, H.H.2
Hansen, M.3
Dombernowsky, P.4
-
61
-
-
34247899113
-
Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?
-
Shi AA, Digumarthy SR, Temel JS et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol 2006; 1: 205-210.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 205-210
-
-
Shi, A.A.1
Digumarthy, S.R.2
Temel, J.S.3
|